Market Intelligence, Clinical Progress, and High-Purity Reagents for Selective Cell Cycle Inhibition Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CDK6 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Kinase | CDK6 Active Kinase / Mutant Recombinant Protein: High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Includes Palbociclib-resistance mutations (F107L, D163G). | View CDK6 Products |
| Gene Delivery | CDK6 Promise-ORF / Lentivirus: Full-length ORF for stable cell lines. Codon-optimized for mammalian expression. | View CDK6 Products |
| Benchmark Ab | Anti-CDK6 (Sequence Verified): Recombinant positive control for Western/IP. | View CDK6 Products |
| Validator | CDK6 siRNA Set: For knockdown verification and specificity confirmation. | View CDK6 Products |
| Related Target CDK4 | CDK4 protein: Critical for selectivity counter-screening (high homology, distinct toxicity profile). | View CDK4 Products |
| Related Target CCND1 | Cyclin D1 (CCND1): Essential activation partner; required for functional kinase complex assays. | View CCND1 Products |
| Related Target CDK2 | CDK2 protein: Resistance bypass pathway and selectivity counter-target. | View CDK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity over CDK4 (avoid thrombocytopenia) | Human CDK4 and CDK6 homolog proteins available with >95% purity; Sequence-verified ATP-binding pocket regions for accurate off-target profiling. |
| Drug Resistance Mutations | CDK6 mutant panel (F107L, D163G, etc.) for mechanistic resistance studies; Theoretical MW confirmed by SEC-MALS. Clinical mutations from dbSNP (rs35654944, rs606231255) and somatic melanoma samples included for development of next-generation inhibitors. |
| PROTAC Ternary Complex Validation | Recombinant proteins optimized for SPR/BLI assays to confirm target-ligand-E3 ligase kinetics. |
| Complex Formation (Cyclin D1) | Co-expression validated proteins available; HEK293 expressed for native folding. |
| Lack of Specificity Controls / False Positives | CDK6-selective siRNA and shRNA Lentivirus included for target validation; Clinical benchmark antibodies included for assay standardization. |
Live CDK6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for next-generation CDK6 therapeutics is intensifying, with major players shifting focus from pan-CDK4/6 inhibitors to CDK6-selective agents and targeted degraders (PROTACs). First-generation CDK4/6 inhibitors (Palbociclib, Ribociclib, Abemaciclib) established the pathway in HR+ breast cancer but exhibit dose-limiting thrombocytopenia driven by CDK4 inhibition. As the field matures, the next wave of R&D targets selective CDK6 inhibition to preserve efficacy while minimizing hematologic toxicity, alongside emerging CNS-penetrant variants for brain metastases. Acquired resistance mutations (e.g., CDK6 F107L, D163G) and bypass mechanisms (CDK2 activation) are driving development of mutant-active inhibitors and combination strategies.
Key Mutations and Resistance Mechanisms
CDK6 mutations identified in clinical samples include dbSNP:rs35654944 (UniProt VAR_041978), dbSNP:rs606231255 associated with MCPH12 (VAR_072638), and a somatic mutation found in a metastatic melanoma sample (VAR_041979). These mutations can alter drug binding or kinase activity. Our reagent portfolio includes recombinant proteins covering these variants to enable resistance mechanism studies and compound profiling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule | Blueprint Medicines, Pfizer | Solid Tumors, Hematologic Malignancies | Selectivity Panel (Need CDK4 vs CDK6 purified proteins for IC50 determination) |
| PROTAC Degraders | Arvinas, C4 Therapeutics, Biogen | Resistant Breast Cancer, Refractory Solid Tumors | Binary/Ternary Complex Formation (Need high-purity CDK6 + Cyclin D1; SPR-ready kinases) |
| CNS-Penetrant Inhibitor | Eli Lilly, Novartis | Brain Metastases, Glioblastoma | Cellular Uptake Assays (Need stable CDK6-overexpressing cell lines via Lentivirus) |
| CDK4/6 Dual Inhibitor (Next-gen) | Daiichi Sankyo, Astellas | HR+ Breast Cancer, Colorectal | Combination Toxicity Profiling (Need CDK4, CDK6, and CDK2 counter-screens) |
| Combination Therapies | Various Biotechs | Metastatic ER+ Breast Cancer | Resistance Modeling (Need Mutant vs WT Proteins) |